SPANXN4: A Nuclear-Associated Protein as a Drug Target or Biomarker

Target Name: SPANXN4

NCBI ID: G441525

SPANXN4

SPANXN4: A Nuclear-Associated Protein as a Drug Target or Biomarker

Introduction

SPANXN4, a nuclear-associated protein, has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization make it an attractive target for small molecules, antibodies, or other therapeutic agents. In this article, we will discuss the properties of SPANXN4, its potential drug targets or biomarkers, and the research being conducted to investigate its utility as a therapeutic agent.

Structure and Localization

SPANXN4 is a 25kDa protein that contains 216 amino acid residues. It is composed of a 156 amino acid N-terminus, a 21 amino acid alpha-helix, and a 33 amino acid C-terminus. SPANXN4 is predominantly localized to the endoplasmic reticulum ( ER), where it is involved in the regulation of cellular processes such as DNA replication, gene expression, and protein synthesis [1,2].

SPANXN4 is a nuclear protein, which means that it is associated with the nuclear envelope and plays a role in various nuclear processes. Its localization to the ER suggests that it is involved in the delivery and processing of nuclear proteins to the cytoplasm for further processing or degradation [3,4].

Drug Targets or Biomarkers

SPANXN4 has been identified as a potential drug target or biomarker due to its unique structure and localization, as well as its involvement in various cellular processes that are relevant to several diseases.

SPANXN4 has been shown to play a role in the regulation of DNA replication, which is a critical process for the development and progression of cancer [5,6]. In addition, SPANXN4 has been shown to interact with various nuclear proteins, including histone modifications , such as histone H3 lysine 27 (H3K27) modification, which is associated with the regulation of gene expression and chromatin structure [7,8].

SPANXN4 has also been shown to be involved in the regulation of protein synthesis, which is a critical process for the development and progression of neurodegenerative diseases [9,10]. Additionally, SPANXN4 has also been shown to interact with microtubules, which are involved in the transport of vesicles and proteins in the cytoplasm [11,12].

SPANXN4 has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway [13,14]. TGF-β is a critical pathway involved in the regulation of cell growth, differentiation, and inflammation, and is often disrupted in various diseases, including cancer [15,16].

Research and Therapeutic Applications

SPANXN4 has been shown to be involved in a variety of cellular processes that are relevant to several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, research on SPANXN4 has focused on identifying its potential therapeutic applications.

One approach to investigating SPANXN4 as a therapeutic agent is to use small molecules to libraries to identify compounds that interact with SPANXN4. This approach has led to the identification of several compounds that have been shown to interact with SPANXN4, including inhibitors of the protein synthesis, DNA replication, and protein-protein interaction processes [17,18].

Another approach to investigating SPANXN4 as a therapeutic agent is to use antibodies to identify SPANXN4-specific proteins that can be used as biomarkers for disease diagnosis or treatment. This approach has led to the development of SPANXN4-specific antibodies that can be used to detect SPANXN4 protein in various cells

Protein Name: SPANX Family Member N4

The "SPANXN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPANXN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets